Show simple item record

dc.contributor.authorDixon, SC
dc.contributor.authorNagle, CM
dc.contributor.authorWentzensen, N
dc.contributor.authorTrabert, B
dc.contributor.authorBeeghly-Fadiel, A
dc.contributor.authorSchildkraut, JM
dc.contributor.authorMoysich, KB
dc.contributor.authordeFazio, A
dc.contributor.authorAustralian Ovarian Cancer Study Group
dc.contributor.authorRisch, HA
dc.contributor.authorRossing, MA
dc.contributor.authorDoherty, JA
dc.contributor.authorWicklund, KG
dc.contributor.authorGoodman, MT
dc.contributor.authorModugno, F
dc.contributor.authorNess, RB
dc.contributor.authorEdwards, RP
dc.contributor.authorJensen, A
dc.contributor.authorKjær, SK
dc.contributor.authorHøgdall, E
dc.contributor.authorBerchuck, A
dc.contributor.authorCramer, DW
dc.contributor.authorTerry, KL
dc.contributor.authorPoole, EM
dc.contributor.authorBandera, EV
dc.contributor.authorPaddock, LE
dc.contributor.authorAnton-Culver, H
dc.contributor.authorZiogas, A
dc.contributor.authorMenon, U
dc.contributor.authorGayther, SA
dc.contributor.authorRamus, SJ
dc.contributor.authorGentry-Maharaj, A
dc.contributor.authorPearce, CL
dc.contributor.authorWu, AH
dc.contributor.authorPike, MC
dc.contributor.authorWebb, PM
dc.date.accessioned2020-12-17T03:22:11Z
dc.date.available2020-12-17T03:22:11Z
dc.date.issued2017-04-25
dc.identifierpii: bjc201768
dc.identifier.citationDixon, S. C., Nagle, C. M., Wentzensen, N., Trabert, B., Beeghly-Fadiel, A., Schildkraut, J. M., Moysich, K. B., deFazio, A., Australian Ovarian Cancer Study Group, Risch, H. A., Rossing, M. A., Doherty, J. A., Wicklund, K. G., Goodman, M. T., Modugno, F., Ness, R. B., Edwards, R. P., Jensen, A., Kjær, S. K. ,... Webb, P. M. (2017). Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.. Br J Cancer, 116 (9), pp.1223-1228. https://doi.org/10.1038/bjc.2017.68.
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/11343/254856
dc.description.abstractBACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited. METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths). RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)). CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.titleUse of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
dc.typeJournal Article
dc.identifier.doi10.1038/bjc.2017.68
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.source.titleBritish Journal of Cancer
melbourne.source.volume116
melbourne.source.issue9
melbourne.source.pages1223-1228
dc.rights.licenseCC BY-NC-SA
melbourne.elementsid1324058
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418444
melbourne.contributor.authorBaglietto, Laura
dc.identifier.eissn1532-1827
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record